UNSPSC 51332207: Carpipramine maleate

This classification denotes an antidepressant agent C28H38N4O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PT5UOX7GI7, chemically known as (1,4'-bipiperidine)-4'-carboxamide, 1'-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-, (2z)-2-butenedioate (1:1), but more generally known as carpipramine maleate, which bears US NIH Compound Identifier 5282174. Most nations, for tariff and trade purposes, schedule carpipramine maleate under HS 29333999 and SITC 51574.

As of Q4 2014, CARPIPRAMINE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)CCC3CCCCC3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332207 Carpipramine maleate is a Commodity code that nominally describes a single pharmaceutical compound, but the recent state and local solicitations tagged under it reflect a much broader scope: state and local health agencies are procuring pharmaceutical products and drug-management systems through this code, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and associated drug deactivation or dispensing infrastructure. The mismatch between the code's narrow nominal scope and the actual purchasing activity suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical procurement rather than strictly for carpipramine maleate itself. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The activity spans both direct product procurement and preliminary market-intelligence gathering around alternative pharmacy delivery models.

Geographic activity concentrates in Florida, Texas, and Minnesota. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to a county health facility; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026. The MMCAP solicitation explicitly weights price competitiveness at 75 percent and requires vendors to maintain contractual relationships with at least two of three designated wholesalers. None of the opportunities specify explicit set-aside or disadvantaged-enterprise restrictions.